Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Thoracic Cancer|January 3, 2023
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancerJing Zhao, Yang Wu, Yuan Yue, et al.
Frontiers in Neuroscience|January 23, 2023
Alterations in brain structure and function associated with pediatric growth hormone deficiency: A multi-modal magnetic resonance imaging studyZhibo Zhou, Yunyun Luo, Xiaoxing Gao, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 11, 2020
[Clinical-radiological-pathological Characteristics of 297 Cases of Surgical Pathology Confirmed Benign Pulmonary Lesions in Which Malignancy Could Not Be Excluded in Preoperative Assessment: A Retrospective Cohort Analysis in a Single Chinese Hospital]Yongjian Liu, Minjiang Chen, Chao Guo, et al.
Asia-Pacific Journal of Oncology Nursing|July 2, 2025
COVID-19 related symptoms and the second infection status of SARS-CoV-2 in patients with lung cancer: A single-center, six-month longitudinal observational studyRuili Pan, Qi He, Nuo Xu, et al.
Translational Lung Cancer Research|January 24, 2022
Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatmentsYuequan Shi, Xiaoyan Liu, Jia Liu, et al.
Translational Lung Cancer Research|December 10, 2025
Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort studyHaoran Zhang, Zhaozhen Wu, Tao Lu, et al.
Scientific Reports|October 14, 2024
Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in BeijingHuaiya Xie, Yaqi Wang, Yan Xu, et al.
Chinese Medical Journal|May 25, 2025
Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational studyYuequan Shi, Xiaoyan Liu, Anwen Liu, et al.
Thoracic Cancer|December 22, 2021
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in ChinaYuequan Shi, Jian Fang, Chengzhi Zhou, et al.
Translational Lung Cancer Research|December 13, 2023
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort studyDongming Zhang, Xiaoyan Liu, Fangfang Shen, et al.
Pageof 4